A human-first, data-driven approach
Freya’s proprietary multi-omics data science platform, Dyscover™, provides deep insights into disease pathway-associated biomarkers and derivation of clinical candidates.
Key capabilities
Largest biobank
Over 1,000 deeply characterized samples derived from both observational and randomized, placebo controlled trials
Multi-omics integration
Genomic, proteomic, and immunologic profiles mapped to each tissue sample
Insights into disease pathways
Identifies novel therapeutic targets and indications
Accelerated clinical translation
Enables intelligent patient stratification for faster breakthroughs
Dyscover™ platform
Closing the data gap, de-risking clinical development and enabling innovation
Unique multi-omics data science platform built on a biobank of:
- +1,000 patients samples
- Intervention data
- Continuing to scale
3-5 yrs lead time and capital intensive to reproduce unique sample collection
Provides deep insights into disease pathway associated markers
Allows for de-risked:
- Target identification
- Patient stratification
- Integration into full AI data platform
Growing industry & scientific consensus
Women’s health conditions like endometriosis are increasingly recognized as systemic inflammatory/immune dysregulation disorders (Lancet 2025)
Hormonal therapies often deliver incomplete and non-durable benefit (JAMA 2025)
Sex differences in immunity must be harnessed to advance treatment (Science 2025)
A proven all in-human discovery platform
Dyscover™ has already generated two first‑in‑class therapeutic candidates.
FB301
Advancing into Phase 2 for IVF‑related embryo implantation failure
FB401
Targeting preterm birth, with bacterial vaginosis as the initial proof‑of‑concept population
Both candidates were developed through the Dyscover™ platform which leverages “in human” discovery to identify strains with superior engraftment and immune modulatory potential.
Copyright © Freya
